# Group Member Tips and Supporting Evidence
These notes combine group-member observations with supporting literature where available.
They are best used as a peer-to-peer discussion, not as direct treatment advice.
Xgeva rebound and Osteonecrosis (ONJ) risk
Stopping denosumab abruptly can trigger rapid rebound in bone turnover.
Multiple vertebral fractures after denosumab cessation have been documented.
Transition to a bisphosphonate such as Zometa before stopping may help reduce this risk.
Osteonecrosis of the jaw is a serious risk with both Xgeva and Zometa.
Risk rises with treatment duration and dental risk factors.
{% hint style="info" %}
**Member note**
*"If you do develop ONJ, you cannot have another bisphosphonate. Many doctors appear to be unaware of the rebound effect or the risk of ONJ. There are support groups online dedicated to these issues."*
{% endhint %}
### Key References
Denosumab Discontinuation and the Rebound Phenomenon\
Transitioning from Xgeva to Zometa
Switching from denosumab to zoledronic acid can bring a tougher acute reaction after the first infusion.
That can include flu-like symptoms, chills, fever, headache, and joint or muscle pain.
These effects often settle within days.
Extending infusion time to 30 minutes rather than 15 may reduce headaches and acute reactions.
{% hint style="info" %}
**Member note**
*"The first Zometa infusion was tougher than Xgeva. I had flu-like symptoms and couldn't leave the couch, but felt better after a few days and noticed an improvement in bone pain."*
{% endhint %}
### Key References
Adverse effect profile of parenteral zoledronic acid\
Zometa dosing intervals with Xgeva or Zometa
Several randomised trials have found that giving Zometa every 12 weeks can be non-inferior to monthly dosing for preventing bone complications in metastatic cancer.
{% hint style="info" %}
**Member note**
*"I have it every 12 weeks, not every month as initially suggested. My oncologist agreed after I showed a study supporting this."*
{% endhint %}
### Key References
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid\
Timing of natural agents with Xgeva or Zometa
Spacing natural agents 2 to 4 hours away from Xgeva or Zometa dosing may be a sensible precaution.
Wenshen Zhuanggu Formula
WSZG is a traditional Chinese herbal formula used as an adjunct in some Chinese hospital settings for breast-cancer patients with bone metastases.
One member also reported diminished spinal lesions on follow-up imaging after use.
Experimental work and small clinical cohorts suggest WSZG may reduce bone metastases and protect bone structure by affecting the tumour microenvironment and osteoclast formation.
Key herbs noted here include:
* Fructus psoraleae
* Fructus cnidii
* Aconiti lateralis radix praeparata
### Key References
Wenshen Zhuanggu formula suppresses breast cancer bone metastases\
Wenshen Zhuanggu formula inhibits tumour-exosome induced bone pre-metastasis niche\
D-limonene
D-limonene appears to be a partial modulator of RANKL-linked activity rather than a substitute for denosumab.
Its likely relevance is as part of a broader adjunctive strategy.
The link below is optional further reading.
d-limonene suppresses RANKL-induced osteoclast differentiation and promotes osteoblast activity in vitro\
AlgaeCal and bone mineral formulas
These were included here as supportive bone-mineral products.
Calcium and vitamin D should still be monitored because the risk of hypocalcaemia rises with both Xgeva and Zometa.
There are arguments both for and against calcium supplementation in cancer settings.
Vitamin D3 and K2
Pairing vitamin D3 with vitamin K2 may help direct calcium toward bone rather than soft tissue.
Daily sunlight exposure may help where possible.
### Bone Metastases in Breast Cancer pages
* [Bone Metastases in Breast Cancer](/myhealingcommunity-docs/breast-cancer/metastatic-disease-support/bone-metastases-in-breast-cancer.md)
* [Xgeva and Zometa](/myhealingcommunity-docs/breast-cancer/metastatic-disease-support/bone-metastases-in-breast-cancer/xgeva-and-zometa.md)
* [Integrative and Off-Label Strategies](/myhealingcommunity-docs/breast-cancer/metastatic-disease-support/bone-metastases-in-breast-cancer/integrative-and-off-label-strategies.md)
* [FOXM1 in Bone Metastasis](/myhealingcommunity-docs/breast-cancer/metastatic-disease-support/bone-metastases-in-breast-cancer/foxm1-in-bone-metastasis.md)
* [Bone Support and Protocol Notes](/myhealingcommunity-docs/breast-cancer/metastatic-disease-support/bone-metastases-in-breast-cancer/bone-support-and-protocol-notes.md)
* [Group Member Tips and Supporting Evidence](/myhealingcommunity-docs/breast-cancer/metastatic-disease-support/bone-metastases-in-breast-cancer/group-member-tips-and-supporting-evidence.md)
### Also relevant
* [SABR for BC Bone Mets 2025 Study Summary](/myhealingcommunity-docs/breast-cancer/metastatic-disease-support/bone-metastases-in-breast-cancer/sabr-for-bc-bone-mets-2025-study-summary.md)
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/metastatic-disease-support/bone-metastases-in-breast-cancer/group-member-tips-and-supporting-evidence.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.